Article Text

Download PDFPDF
EP523 Preliminary assessing the indication of MPA therapy for early endometrial cancer in the pregnancy point of view
  1. T Furui,
  2. M Takenaka,
  3. K Terazawa,
  4. S Aikyo,
  5. K Kikuno,
  6. S Yamamoto,
  7. T Shiga,
  8. R Shimaoka and
  9. K-I Morishige
  1. Obstetrics and Gynecology, Gifu University Hospital, Gifu, Japan


Introduction/Background High-dose MPA therapy is used as a fertility-sparing treatment for atypical endometrial hyperplasia (AEH) and early stage endometrial cancer(EC). However, this treatment has problems such as uncertain therapeutic effect and high recurrence rate. We studied the indication of ‘start and continuation of MPA therapy’ in the reproductive point of view.

Methodology Patients: Twelve patients who attempted pregnancy with after treatment with MPA in our hospital from June 2006 to February 2019. Measurement: age, BMI, duration of MPA therapy, the presence of Polycystic ovaries findings in ultrasonography (USPCO) and ovulatory disorder were compared in the pregnancy group and the non-pregnancy group.

Results In pregnancy group and non-pregnancy, average age was 30.2±2.17, 35.1±3.8 (p=0.028), BMI was 21.6±3.21, 28.3±6.78 (p=0.062), MPA treatment period (months) was 6.80±6.06, 28.0±16.7 (p=0.051), respectively.

Conclusion In considering the choice and continuation of MPA therapy, it should be more important to sufficiently explain the benefits and risks of this treatment, especially for the elderly, those with high BMI, and those with long-term treatment continuation in the point of pregnancy outcome.

Disclosure Nothing to disclose.

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.